#None #London #VolitionRx #Early Cancer Detection #Capture-Seq

VolitionRx Introduces Breakthrough Cancer Detection Technology

At the recent ESMO MAP Conference held in London, VolitionRx Limited (NYSE AMERICAN: VNRX), a global leader in the field of epigenetics, made headlines with its presentation of a pioneering technology for detecting early-stage solid cancers. The abstract titled "Early Stage I Solid Cancer Detection by Direct ChIP-seq of Short CTCF-Protected Plasma ctDNA" was presented by Dr. Andrew Retter, a medical consultant at the company.

This new method innovatively utilizes the Capture-Seq™ technology to identify solid cancers at stage I, potentially revolutionizing early cancer diagnosis. Dr. Retter expressed excitement about the opportunity to present during such a prestigious event, emphasizing the promising early validation results derived from their research.

In initial trials involving two independent cohorts, VolitionRx reported an impressive record: no false positives and accurate identification of cancer in every patient tested in the first cohort. This cohort included 23 patients diagnosed with early stage I/II cancers as well as 21 healthy controls. The second cohort, which was blinded, confirmed the detection of 13 out of 14 later-stage cancers alongside 10 additional healthy control subjects.

What makes these findings particularly noteworthy is the subsequent validation conducted on a larger cohort comprising 81 participants, where 95% of early-stage cancer cases were successfully detected. This high sensitivity in identifying stage I and II cancers suggests significant potential for the Adoption of Capture-Seq™ in the medical landscape, paving the way toward a much-needed solution for early cancer detection, which is crucial for improving patient outcomes.

Dr. Jake Micallef, the Chief Scientific Officer of Volition, elaborated on the technology stating that Capture-Seq™ analyzes the unique CTCF-protected ctDNA from the background cell-free DNA. This leads to a wealth of sequencing data that is distinguishable in blood samples from early-stage cancer patients but absent in those from healthy individuals.

This methodological advancement positions Capture-Seq™ not only as a vital tool for early cancer detection but also holds promise in cancer management strategies, including monitoring Minimal Residual Disease (MRD), either in isolation or conjunction with existing technologies. VolitionRx is set on an accelerated path to further develop this technology, collaborating alongside oncology experts to enhance the scope and application of their findings.

The discussion around the potential market for early cancer detection is significant, with estimates suggesting a total addressable market of around $36 billion. VolitionRx is carving its niche in this space with innovative solutions tailored towards early detection and treatment monitoring in oncology.

Volition plays a crucial role in the evolving landscape of liquid biopsy technologies. By focusing on circulating cell-free nucleoproteins, the company aims to enhance early detection systems for various cancers while addressing the critical needs surrounding disease management. They have already initiated several patent filings to secure their innovations in this promising field.

As the industry anticipates further studies and trials, the importance of conferences such as ESMO MAP cannot be overstated. They foster an environment for collaboration and innovation among experts, paving the way for advancements in cancer diagnostics and treatments. This critical dialogue helps lay the groundwork for breakthroughs that could ultimately save lives and enhance quality of life for cancer patients worldwide.

With VolitionRx at the forefront, the future of early cancer detection looks brighter than ever, reminding us of the significant impact that innovative technologies can have on healthcare today.